Hyperthyroidism increases adenosine transport and metabolism in the rat heart.
Hyperthyroidism induces a number of metabolic and physiological changes in the heart including hypertrophy, increase in inotropic status, and alterations of myocardial energy metabolism. The effects of hyperthyroidism on adenosine metabolism which is intimately involved in the control of many aspects of myocardial energetics, have not been clarified. The aim of this study was thus to evaluate the potential role of adenosine in the altered physiology of the hyperthyroid heart. Transport of adenosine was studied in cardiomyocytes isolated from hyperthyroid and euthyroid rats. Activities of different enzymes of purine metabolism were studied in heart homogenates and concentrations of nucleotide and creatine metabolites were determined in hearts freeze-clamped in situ. Both transport of adenosine into cardiomyocytes and the rate of intracellular phosphorylation were higher in the hyperthyroid rat. At 10 microM concentration, adenosine transport rates were 275 and 197 pmol/min/mg protein in hyperthyroid and euthyroid cardiomyocytes respectively whilst rates of adenosine phosphorylation were 250 and 180 pmol/min/mg prot. An even more pronounced difference was observed if values were expressed per number of cells due to cardiomyocyte enlargement. Hyperthyroidism was associated with a 20% increase in adenosine kinase, 30% decrease in membrane 5'-nucleotidase and 15% decrease in adenosine deaminase activities measured in heart homogenates. In addition there was a substantial depletion in the total creatine pool from 63.7 to 41.6 mumol/g dry wt, a small decrease in the adenylate pool (from 27.2 to 24.3 mumol/g dry wt) and an elevation of the guanylate pool (from 1.22 to 1.36). These results show that adenosine transport and phosphorylation capacity is enhanced in hyperthyroidism.(ABSTRACT TRUNCATED AT 250 WORDS)
Smolenski
R T
RT
Department of Cardiothoracic Surgery, National Heart and Lung Institute at Harefield Hospital, Middlesex, UK.
Yacoub
M H
MH
Seymour
A M
AM
D000659:AMP Deaminase / Q000032:analysis / Q000378:metabolism; D000225:Adenine / Q000378:metabolism; D000241:Adenosine / Q000378:metabolism*; D000243:Adenosine Deaminase / Q000032:analysis / Q000378:metabolism; D000248:Adenosine Kinase / Q000032:analysis / Q000378:metabolism; D043383:Adenosylhomocysteinase; D000818:Animals; D001692:Biological Transport; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D006321:Heart / Q000033:anatomy & histology / Q000187:drug effects; D006867:Hydrolases / Q000032:analysis / Q000378:metabolism; D006980:Hyperthyroidism / Q000139:chemically induced / Q000378:metabolism*; D008297:Male; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D009708:Nucleotidases / Q000032:analysis / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D010766:Phosphorylation; D011683:Purine-Nucleoside Phosphorylase / Q000032:analysis / Q000378:metabolism; D051381:Rats; D013974:Thyroxine / Q000494:pharmacology; D013997:Time Factors; D014969:Xanthine Oxidase / Q000032:analysis / Q000378:metabolism
D014969:Xanthine Oxidase; D011683:Purine-Nucleoside Phosphorylase; D000248:Adenosine Kinase; D006867:Hydrolases; D009708:Nucleotidases; D043383:Adenosylhomocysteinase; D000243:Adenosine Deaminase; D000659:AMP Deaminase; D000225:Adenine; D000241:Adenosine; D013974:Thyroxine